NEW YORK (GenomeWeb News) – Protagen today announced that Scienion will produce protein microarray batches of more than 1,000 arrays for Protagen for the clinical validation of biomarker panels.
In addition, under a strategic partnership, the two Dortmund, Germany-based firms will jointly evaluate new platforms for multiplexed analytics and co-develop new approaches up to proof-of-concept levels.
Financial and other terms of the deal were not disclosed.
Peter Schulz-Knappe, CSO of Protagen, said in a statement that Scienion's sciFlexarrayer nanodispensing technology allows for the manufacture of protein microarray batches, each with more than 3,500 single proteins with "the highest quality and reproducibility."